Glucose and cholesterol absorption

Glucose and cholesterol absorption refers to the physiological process by which the small intestine takes up dietary sugars and lipids into the systemic circulation. This is not a single molecular target but a complex mechanism involving multiple distinct proteins, most notably Niemann-Pick C1-like 1 (NPC1L1) for cholesterol and Sodium-glucose cotransporter 1 (SGLT1) for glucose (Altmann et al., Science 2004; Wright et al., Physiol Rev 2011). In the context of metabolic disease, excessive absorption of these nutrients leads to hyperglycemia and hypercholesterolemia, which are primary drivers of type 2 diabetes and atherosclerotic cardiovascular disease (NIH StatPearls, 2023). Pharmacological agents like ezetimibe and acarbose target specific components of these pathways to reduce the systemic influx of nutrients. While effective for managing metabolic parameters, these interventions often cause gastrointestinal side effects due to the osmotic activity or fermentation of unabsorbed nutrients in the colon. Because the term encompasses multiple unrelated transport systems and enzymes, it is classified as a physiological process rather than a specific therapeutic target.

Other names

Intestinal nutrient absorptionEnterocyte glucose and lipid transportDietary carbohydrate and fat uptake

Inhibition of specific intestinal brush border transporters such as Niemann-Pick C1-like 1 (NPC1L1) for cholesterol and Sodium-glucose cotransporter 1 (SGLT1) for glucose, or the inhibition of enzymes like alpha-glucosidase that break down complex sugars (Altmann et al., 2004; Wright et al., 2011).